Clinical Trial Update: Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluated epigallocatechin-3-gallate (EGCG) supplementation in traumatic brain injury patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Epigallocatechin-3-Gallate (epigallocatechin-3-gallate)

Snippet

Sponsor: National Nutrition and Food Technology Institute | Conditions: Traumatic Brain Injury | Phase 2, Phase 3 | Status: COMPLETED